The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 344:673-675 March 1, 2001 Number 9
NextNext

Redesigning Heparin

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Turpie, A. G.G.
-Related Article
 by Blendon, R. J.
The anticoagulant mechanism of heparin was obscure until 1973,1 when it was found that heparin enhances by as much as 1000 times the ability of the plasma protein antithrombin to form complexes with thrombin, factor Xa, and factor IXa, thereby inhibiting their activity and acting as an anticoagulant. Three years later, Lam et al. showed that only a small fraction of heparin binds to purified antithrombin, yet this fraction possesses virtually all of the anticoagulant activity of heparin.2 The region responsible for the anticoagulant activity of heparin has a unique oligosaccharide structure — the antithrombin-binding domain. Lindahl et al. made . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.